Texas Bank & Trust Co Makes New Investment in Pfizer Inc. (NYSE:PFE)

Texas Bank & Trust Co bought a new position in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 35,568 shares of the biopharmaceutical company’s stock, valued at approximately $944,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the 4th quarter valued at about $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter valued at about $28,000. Finally, Noble Wealth Management PBC acquired a new position in shares of Pfizer during the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.0%

Shares of NYSE:PFE opened at $22.83 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $129.77 billion, a PE ratio of 16.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The firm’s 50-day moving average is $23.65 and its two-hundred day moving average is $25.34. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.82 earnings per share. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Ratings Changes

Several research analysts have recently weighed in on PFE shares. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.